NASDAQ:HSGX - Histogenics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.37 -0.06 (-2.47 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$2.43
Today's Range$2.35 - $2.50
52-Week Range$1.60 - $3.35
Volume49,500 shs
Average Volume102,812 shs
Market Capitalization$68.85 million
P/E Ratio-2.42
Dividend YieldN/A
Beta1.62
Histogenics logoHistogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.

Receive HSGX News and Ratings via Email

Sign-up to receive the latest news and ratings for HSGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HSGX
CUSIPN/A
Phone781-547-7900

Debt

Debt-to-Equity RatioN/A
Current Ratio1.94
Quick Ratio1.94

Price-To-Earnings

Trailing P/E Ratio-2.42
Forward P/E Ratio-4.47
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.46) per share
Price / Book-5.15

Profitability

EPS (Most Recent Fiscal Year)($0.98)
Net Income$-26,410,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-140.82%

Miscellaneous

Employees45
Outstanding Shares28,690,000
Market Cap$68.85

Histogenics (NASDAQ:HSGX) Frequently Asked Questions

What is Histogenics' stock symbol?

Histogenics trades on the NASDAQ under the ticker symbol "HSGX."

How were Histogenics' earnings last quarter?

Histogenics Corp (NASDAQ:HSGX) posted its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.45. View Histogenics' Earnings History.

When is Histogenics' next earnings date?

Histogenics is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Histogenics.

What price target have analysts set for HSGX?

2 brokerages have issued twelve-month price targets for Histogenics' shares. Their predictions range from $4.00 to $4.00. On average, they expect Histogenics' stock price to reach $4.00 in the next year. This suggests a possible upside of 68.8% from the stock's current price. View Analyst Ratings for Histogenics.

What is the consensus analysts' recommendation for Histogenics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Histogenics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Histogenics' key competitors?

Who are Histogenics' key executives?

Histogenics' management team includes the folowing people:
  • Mr. Adam D. Gridley, Pres, CEO & Director (Age 46)
  • Mr. Jonathan I. Lieber, Chief Financial Officer (Age 48)
  • Mr. Stephen R. Kennedy, Exec. VP & COO (Age 61)
  • Dr. Donald D. Haut, Chief Bus. Officer (Age 52)
  • Mr. Peter Hamilton, VP of Operations & Engineering (Age 54)

When did Histogenics IPO?

(HSGX) raised $60 million in an IPO on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

Has Histogenics been receiving favorable news coverage?

News headlines about HSGX stock have been trending somewhat positive recently, according to Accern. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Histogenics earned a news impact score of 0.15 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 46.04 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Histogenics?

Shares of HSGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Histogenics' stock price today?

One share of HSGX stock can currently be purchased for approximately $2.37.

How big of a company is Histogenics?

Histogenics has a market capitalization of $68.85 million. The biotechnology company earns $-26,410,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Histogenics employs 45 workers across the globe.

How can I contact Histogenics?

Histogenics' mailing address is 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-547-7900 or via email at [email protected]


MarketBeat Community Rating for Histogenics (NASDAQ HSGX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  200 (Vote Outperform)
Underperform Votes:  141 (Vote Underperform)
Total Votes:  341
MarketBeat's community ratings are surveys of what our community members think about Histogenics and other stocks. Vote "Outperform" if you believe HSGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.